<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5DBE339EDC2543E89CF64A2C80D63AD1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 3012 IH: Right to Try Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-07-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3012</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150709">July 9, 2015</action-date>
			<action-desc><sponsor name-id="S000018">Mr. Salmon</sponsor> (for himself, <cosponsor name-id="S001188">Mr. Stutzman</cosponsor>, and <cosponsor name-id="G000565">Mr. Gosar</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To authorize the use of unapproved medical products by patients diagnosed with a terminal illness
			 in accordance with State law, and for other purposes.</official-title>
	</form>
	<legis-body id="H407A0B25A1244C85B4AE89E0238DA90B" style="OLC">
 <section id="HCCB55BAF683340C19D1A2E96F43DCFEA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Right to Try Act of 2015</short-title></quote>.</text> </section><section id="H7029BFBD99D24D9D8D1E25C722F0CD4E"><enum>2.</enum><header>Use of unapproved medical products by patients diagnosed with a terminal illness</header> <subsection id="HBFA9E2325CD044A395FE83526FFCD107"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>), the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>), and any other provision of Federal law, the Federal Government shall not take any action to prohibit or restrict the production, manufacture, distribution, prescribing, dispensing, possession, or use of an experimental drug, biological product, or device that—</text>
 <paragraph id="H59ABB64992864026AFC80E447C6A0D63"><enum>(1)</enum><text>is intended to treat a patient who has been diagnosed with a terminal illness; and</text> </paragraph><paragraph id="H4FC776676E0544948DCFF80DC949EBA7"><enum>(2)</enum><text>is authorized by, and in accordance with, State law.</text>
 </paragraph></subsection><subsection id="HC948E8AEEFC34A56BB20CC792DF16F2B"><enum>(b)</enum><header> Definitions</header><text>In this section:</text> <paragraph id="H254916E060A14F5B891B84514DC32A7D"><enum>(1)</enum><text>The term <term>biological product</term> has the meaning given to such term in section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text>
 </paragraph><paragraph id="H80E1F057F4A3419FBCD43F726C669805"><enum>(2)</enum><text>The terms <term>device</term> and <term>drug</term> have the meanings given to such terms in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text>
 </paragraph><paragraph id="HD9FF24E8514D4255989EA44D14120237"><enum>(3)</enum><text>The term <term>experimental drug, biological product, or device</term> means a drug, biological product, or device that—</text> <subparagraph id="HE34187F9FF11455E87B14CDC23751F9B"><enum>(A)</enum><text>has successfully completed a phase 1 clinical investigation;</text>
 </subparagraph><subparagraph id="HF92517C9D9EF4B518E28CC1178795A7F"><enum>(B)</enum><text>remains under investigation in a clinical trial approved by the Food and Drug Administration; and</text> </subparagraph><subparagraph id="H8E8B13496415475FAE79D5DE9B267FD9"><enum>(C)</enum><text display-inline="yes-display-inline">is not approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of the Federal Food, Drug, or Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), 360(e)) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text>
 </subparagraph></paragraph><paragraph id="H5C204E68272C487B9632B022DF845845"><enum>(4)</enum><text>The term <term>phase 1 clinical investigation</term> means a phase 1 clinical investigation, as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulations).</text>
 </paragraph><paragraph id="H792FA65F2377423499B6C1714247F39E"><enum>(5)</enum><text>The term <term>terminal illness</term> has the meaning given to such term in the State law specified in subsection (a)(2).</text> </paragraph></subsection></section></legis-body> </bill> 

